Surface Oncology
United States
111 articles about Surface Oncology
-
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
5/20/2020
Surface Oncology announced it has entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA®, the first anti-PD-1 therapy approved in the United States.
-
Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting
5/15/2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced five scientific posters sharing updated preclinical data at the American Association for Cancer Research (AACR) 2020 Annual Meeting, to be held virtually on June 22-24. The posters include preclinical data from Surface Oncology’s two lead clinical-stage antibody thera
-
Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting
5/14/2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31. A summary is provided below; the full poster will be
-
Surface Oncology to Present at the UBS Virtual Global Healthcare Conference
5/13/2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its chief executive officer, Jeff Goater, will present at the upcoming UBS Virtual Global Healthcare Conference, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27). The presentation will take place virtually on Wednesday
-
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020
5/12/2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2020, as well as anticipated corporate milestones for 2020. “I am pleased to report that Surface has made substantial clinical progress to date in 2020; achieving important milestones with both of our hig
-
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
4/23/2020
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that it has initiated a Phase 1 clinical trial of its first-in-class antibody SRF388, which targets the immunosuppressive cytokine IL-27.
-
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
3/17/2020
Surface Oncology today announced that it has initiated a Phase 1/1b clinical trial of its antibody candidate SRF617, which targets the immunosuppressive protein CD39. “Our comprehensive preclinical data indicate SRF617 is a potent inhibitor of CD39, which may play an important role in tumor growth
-
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2019
3/10/2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full year 2019, as well as anticipated corporate milestones for 2020. “We have made tremendous progress readying our lead programs, SRF617 and SRF388, for clinical trials. With opened INDs for both
-
Surface Oncology to Present at the 40th Annual Cowen Healthcare Conference
2/25/2020
Surface Oncology announced that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief medical officer, will participate in a fireside chat at the 40th Annual Cowen Healthcare Conference, discussing Surface Oncology's lead programs, SRF617 and SRF388.
-
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
1/27/2020
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) applications for its antibody candidates,
-
Surface Oncology to Present at Evercore ISI 2nd Annual HealthCONx Conference
11/26/2019
Surface Oncology announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief scientific officer, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference.
-
Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures
11/25/2019
Surface Oncology announced it has secured a debt financing facility for up to $25 million from K2 HealthVentures, a healthcare-focused specialty finance company.
-
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2019R&D day on November 18, 2019 in New York City will detail pipeline activity and a new program targeting the immune checkpoint protein CD112R
11/12/2019
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported financial results and corporate highlights for the third quarter of 2019.
-
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual MeetingCompany to provide additional updates at its inaugural R&D day on November 18th in New York
11/7/2019
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present at the Society for the Immunotherapy of Cancer’s (SITC) 34th Annual Meeting in National Harbor, MD.
-
Shares of the company stock plunged in premarket trading after Surface Oncology announced it was scaling back its lead program.
-
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
-
Only days after UK-based Mereo BioPharma canceled its plans for an initial public offering (IPO) on the Nasdaq Global Market, Framingham, Massachusetts-based Alzheon dropped its IPO plans.
-
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.
-
Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
3/20/2018
SRF231 is a fully human antibody that inhibits the activity of CD47, a protein overexpressed on many types of cancer cells which prevents them from being engulfed and eliminated by macrophages.
-
Mr. Goater succeeds interim chief executive officer Dan Lynch, who will remain executive chairman of Surface’s board of directors.